Grant: Banting Postdoctoral Fellowship Program
Direct Payment
$140,000.00
Development and evaluation of second primary lung cancer screening in lung cancer survivors
EF 2024-25
Résumé
Lung cancer (LC) is the most diagnosed cancer and the leading cause of cancer deaths worldwide. To reduce LC deaths, many countries, including Canada and the US, have implemented LC screening programs based on advanced medical imaging which can detect LC at an early stage. In addition, with more effective drugs for LC, the number of LC survivors has increased dramatically in recent years. However, LC survivors are not protected from developing second primary lung cancer (SPLC), a new cancer distinct from recurrence, with those diagnosed with SPLC experiencing twice the mortality of those who are not. This growing burden calls for an effective LC screening program for LC survivors, which is currently lacking in practice.
The overarching goal of my research is to reduce the overall burden of LC deaths through development of cost-efficient screening programs in three steps. The first step is to develop a prediction model for SPLC using large electronic health record datasets that combine academic healthcare and community-based healthcare systems linked through national cancer registries. This prediction model will be able to incorporate changes in individual characteristics, such as smoking status, over time and to provide accurate and timely prediction of SPLC risk. This allows for identification and prioritization of high-risk LC survivors for SPLC screening. The second step is to perform a rigorous causal inference analysis, called a target trial emulation, to evaluate the efficacy of prediction model-based screening for SPLC on the reduction in LC deaths among LC survivors. In the final step, I will use a computer simulation model to evaluate the value-for-money potential of the model-based screening program and provide numeric metrics that can help stakeholders (e.g., patients, doctors, and governments) decide whether to implement this screening program for LC survivors.
Programme
Banting Postdoctoral Fellowship Program
Bénéficiaire
Emplacement
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
511809
Name
Lee Tae Yoon
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Population and Public Health
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Development and evaluation of second primary lung cancer screening in lung cancer survivors
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Health Policy Modeling; Lung Cancer; Microsimulation; Real-World Data Analytics; Risk Prediction Modeling; Screening; Target Trial Emulation
Abstract
Lung cancer (LC) is the most diagnosed cancer and the leading cause of cancer deaths worldwide. To reduce LC deaths, many countries, including Canada and the US, have implemented LC screening programs based on advanced medical imaging which can detect LC at an early stage. In addition, with more effective drugs for LC, the number of LC survivors has increased dramatically in recent years. However, LC survivors are not protected from developing second primary lung cancer (SPLC), a new cancer distinct from recurrence, with those diagnosed with SPLC experiencing twice the mortality of those who are not. This growing burden calls for an effective LC screening program for LC survivors, which is currently lacking in practice.
The overarching goal of my research is to reduce the overall burden of LC deaths through development of cost-efficient screening programs in three steps. The first step is to develop a prediction model for SPLC using large electronic health record datasets that combine academic healthcare and community-based healthcare systems linked through national cancer registries. This prediction model will be able to incorporate changes in individual characteristics, such as smoking status, over time and to provide accurate and timely prediction of SPLC risk. This allows for identification and prioritization of high-risk LC survivors for SPLC screening. The second step is to perform a rigorous causal inference analysis, called a target trial emulation, to evaluate the efficacy of prediction model-based screening for SPLC on the reduction in LC deaths among LC survivors. In the final step, I will use a computer simulation model to evaluate the value-for-money potential of the model-based screening program and provide numeric metrics that can help stakeholders (e.g., patients, doctors, and governments) decide whether to implement this screening program for LC survivors.
Competitiondate
202409
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Lee, Tae Yoon
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~